This case report describes the use of targeted intracordal bevacizumab therapy for recurrent vocal fold hemorrhage refractory to conventional treatment. The intervention was associated with resolution of hemorrhagic episodes and sustained clinical improvement over follow-up. These findings suggest a potential role for antiangiogenic therapy in selected cases.
Volz et al. (Mon,) studied this question.